Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	7,903	6,893	5,012	4,264	2,549	1,896
Market Cap Growth	29.84%	37.53%	17.54%	67.27%	34.44%	204.17%
Enterprise Value	7,442	6,410	4,438	3,875	1,919	1,695
PE Ratio	-	-49.35	-19.56	-15.01	-11.23	-12.83
PS Ratio	15.38	14.84	20.02	50.88	111.74	31280.52
PB Ratio	13.18	11.65	7.64	10.20	3.88	9.72
P/FCF Ratio	-68.00	-55.38	-18.50	-16.41	-11.07	-14.73
P/OCF Ratio	-68.18	-55.50	-18.55	-16.43	-11.08	-14.81
EV/Sales Ratio	14.48	13.80	17.73	46.24	84.13	27966.58
EV/EBITDA Ratio	-57.04	-46.28	-17.36	-13.67	-8.48	-11.51
EV/EBIT Ratio	-56.77	-46.10	-17.32	-13.64	-8.46	-11.48
EV/FCF Ratio	-63.32	-51.50	-16.38	-14.91	-8.33	-13.17
Debt / Equity Ratio	0.03	0.03	0.03	0.06	0.04	0.12
Debt / EBITDA Ratio	-0.15	-0.12	-0.08	-0.09	-0.13	-0.16
Debt / FCF Ratio	-0.17	-0.14	-0.07	-0.10	-0.13	-0.18
Quick Ratio	4.51	4.97	8.04	8.13	18.17	6.18
Current Ratio	5.12	5.41	8.87	8.76	18.75	6.36
Asset Turnover	0.71	0.65	0.31	0.14	0.04	0
Return on Equity (ROE)	-18.50%	-23.00%	-35.90%	-54.90%	-41.70%	-61.10%
Return on Assets (ROA)	-15.30%	-19.40%	-31.90%	-48.40%	-37.70%	-49.90%
Return on Capital (ROIC)	-21.42%	-26.20%	-38.99%	-64.45%	-33.71%	-70.60%
Earnings Yield	-1.40%	-2.03%	-5.11%	-6.66%	-8.91%	-7.79%
FCF Yield	-1.25%	-1.81%	-5.41%	-6.09%	-9.04%	-6.79%
Buyback Yield / Dilution	-1.83%	-1.95%	-15.74%	-15.47%	-27.50%	-0.87%
Total Shareholder Return	-1.83%	-1.95%	-15.74%	-15.47%	-27.50%	-0.87%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).